Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non Operating Income (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Non Operating Income data on record, last reported at $3.5 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 168.2% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $6.6 million, up 33.7%, while the annual FY2025 figure was $6.6 million, 31.8% up from the prior year.
  • Non Operating Income reached $3.5 million in Q4 2025 per TARS's latest filing, up from $98000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.5 million in Q4 2025 and bottomed at -$3.0 million in Q3 2023.
  • Average Non Operating Income over 5 years is $427500.0, with a median of $52000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: plummeted 43028.57% in 2023, then surged 32450.0% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$1.6 million in 2021, then soared by 130.91% to $481000.0 in 2022, then dropped by 24.53% to $363000.0 in 2023, then skyrocketed by 260.33% to $1.3 million in 2024, then soared by 168.2% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $3.5 million in Q4 2025, $98000.0 in Q3 2025, and $3.1 million in Q2 2025.